Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor

Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 104; no. 9; pp. 1277 - 1285
Main Authors Bousquet, Corinne, Susini, Christiane, Melmed, Shlomo
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.11.1999
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2.
AbstractList Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2.
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2.Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2.
Author Melmed, Shlomo
Bousquet, Corinne
Susini, Christiane
AuthorAffiliation 1 Department of Medicine, Cedars-Sinai Research Institute–University of California–Los Angeles School of Medicine, Los Angeles, California 90048, USA 2 Institut National de la Santé et de la Recherche Médicale (INSERM) U151, Institut Louis Bugnard, 31054 Toulouse, France
AuthorAffiliation_xml – name: 1 Department of Medicine, Cedars-Sinai Research Institute–University of California–Los Angeles School of Medicine, Los Angeles, California 90048, USA 2 Institut National de la Santé et de la Recherche Médicale (INSERM) U151, Institut Louis Bugnard, 31054 Toulouse, France
Author_xml – sequence: 1
  givenname: Corinne
  surname: Bousquet
  fullname: Bousquet, Corinne
– sequence: 2
  givenname: Christiane
  surname: Susini
  fullname: Susini, Christiane
– sequence: 3
  givenname: Shlomo
  surname: Melmed
  fullname: Melmed, Shlomo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/10545526$$D View this record in MEDLINE/PubMed
BookMark eNplkU1PwzAMhnMAwQaIf4ByglMhH03XHjigiY-hSSANzlGaJhBIk5K0oP17MjHQgJMl-7Ff-_UYbDnvFACHGJ1iPCFnt9PZpCL5FhghRHBWTWi5C8YxviCE85zlO2AXI5YzRooRGGbu2dSm92EJg7cqQu0DXNzcZxgK18DF3XSR0ZS01n8Y9wQ70w-mFwnvgved8a2ywnnpQ28cNK4ZZG-8g_USWjW8qtaIlP3R0EKmuA-2tbBRHazjHni8unyY3mTzu-vZ9GKeyZyiPmMVaxSVSpd1U7KaiILqJteCEYRZIUvZaKy1KFBJhS5JLTFpUKGQ1KRGE0HpHjj_mtsNdasaqVwfhOVdMG26gHth-O-KM8_8yb_zHFUlYan_eN0f_NugYs9bE6Wy6WLlh8iLilBWopXQ0abQj8K30Qk4-QJk8DEGpTcQvnobX78tkdkfUia_V56mDY39x38CW2KedQ
CitedBy_id crossref_primary_10_1002_mas_20039
crossref_primary_10_1016_S0167_4889_02_00321_X
crossref_primary_10_1016_j_cellsig_2007_07_018
crossref_primary_10_3390_cancers6020897
crossref_primary_10_1074_jbc_M110_161869
crossref_primary_10_3748_wjg_v25_i17_2058
crossref_primary_10_1074_jbc_M401359200
crossref_primary_10_1074_jbc_M003986200
crossref_primary_10_1016_j_cytogfr_2004_06_002
crossref_primary_10_1074_jbc_M505266200
crossref_primary_10_1530_ERC_16_0206
crossref_primary_10_1016_S0169_328X_02_00452_7
crossref_primary_10_1242_dev_00578
crossref_primary_10_1111_j_1471_4159_2008_05759_x
crossref_primary_10_1016_S1155_1941_05_38891_3
crossref_primary_10_1172_JCI11182
crossref_primary_10_1007_BF03346713
crossref_primary_10_1046_j_1471_4159_2000_0742021_x
crossref_primary_10_2337_diabetes_53_9_2232
crossref_primary_10_1242_jcs_113_16_2813
crossref_primary_10_1002_ijc_27655
crossref_primary_10_1021_acschembio_5b00945
crossref_primary_10_1517_13543776_12_10_1537
crossref_primary_10_1084_jem_194_2_189
crossref_primary_10_1186_s13046_019_1206_z
crossref_primary_10_1186_s13148_016_0279_1
crossref_primary_10_1371_journal_ppat_1002229
crossref_primary_10_1530_rep_1_00304
crossref_primary_10_1002_stem_470
crossref_primary_10_1210_endrev_bnac010
crossref_primary_10_1073_pnas_100135197
crossref_primary_10_4049_jimmunol_178_3_1870
crossref_primary_10_1006_phrs_2000_0725
crossref_primary_10_1016_j_jneuroim_2005_08_015
crossref_primary_10_1016_S0014_5793_02_03842_5
crossref_primary_10_1002_jnr_10145
crossref_primary_10_1182_blood_V97_12_3860
crossref_primary_10_1016_S0378_5955_03_00370_8
crossref_primary_10_1016_j_ejcb_2013_03_003
crossref_primary_10_1593_neo_07463
crossref_primary_10_1016_S0006_291X_02_02307_0
crossref_primary_10_1172_JCI200114662
crossref_primary_10_1210_en_2003_0897
crossref_primary_10_1042_CBI20090466
crossref_primary_10_1097_00008469_200608000_00006
crossref_primary_10_1172_JCI200114660
crossref_primary_10_1371_journal_pone_0086330
crossref_primary_10_1002_jnr_20155
crossref_primary_10_1182_blood_V99_7_2351
crossref_primary_10_3390_cancers16030492
crossref_primary_10_1242_jcs_113_23_4331
crossref_primary_10_1158_0008_5472_CAN_04_4359
crossref_primary_10_1016_j_neo_2014_06_005
crossref_primary_10_1113_expphysiol_2006_036236
crossref_primary_10_1038_srep21132
crossref_primary_10_1158_0008_5472_CAN_15_0412
crossref_primary_10_1097_MPA_0000000000000496
crossref_primary_10_3109_08977194_2012_660936
crossref_primary_10_3389_fimmu_2020_00414
crossref_primary_10_1016_j_jmb_2007_12_038
crossref_primary_10_1006_cyto_2001_0887
crossref_primary_10_1016_j_emcend_2005_08_001
crossref_primary_10_1007_BF02981953
crossref_primary_10_1021_jm300207s
crossref_primary_10_1089_107999002760274863
crossref_primary_10_1074_jbc_M710462200
crossref_primary_10_1074_jbc_M007373200
crossref_primary_10_1152_ajpendo_00442_2001
Cites_doi 10.1074/jbc.273.12.7099
10.1126/science.7716523
10.1074/jbc.272.16.10551
10.1172/JCI117779
10.1023/A:1009966808106
10.1038/43213
10.1073/pnas.96.12.6964
10.1021/bi00255a030
10.1128/MCB.16.12.6985
10.1016/0168-9525(94)90149-X
10.1128/MCB.15.12.7050
10.1182/blood.V85.1.87.bloodjournal85187
10.1007/BF00202068
10.1074/jbc.273.3.1285
10.1016/S0065-2776(08)60582-9
10.1074/jbc.272.28.17694
10.1016/S1097-2765(00)80062-3
10.1210/endo.139.5.6016
10.1016/S0968-0004(96)10059-1
10.1074/jbc.272.17.11128
10.1016/S0955-0674(97)80067-1
10.1073/pnas.95.22.13130
10.1128/MCB.19.7.4980
10.1101/gad.12.24.3872
10.1210/mend.12.7.0140
10.1002/j.1460-2075.1995.tb00243.x
10.1172/JCI118615
10.1074/jbc.270.31.18179
10.1093/emboj/18.2.375
10.1073/pnas.95.1.114
10.1002/j.1460-2075.1995.tb07281.x
10.1126/science.273.5282.1717
10.1074/jbc.272.37.23376
10.1210/endo.137.7.8770918
10.1074/jbc.274.16.10723
10.1016/0092-8674(95)90351-8
ContentType Journal Article
Copyright Copyright © 1999, American Society for Clinical Investigation 1999
Copyright_xml – notice: Copyright © 1999, American Society for Clinical Investigation 1999
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1172/JCI7924
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 1285
ExternalDocumentID PMC409825
10545526
10_1172_JCI7924
Genre Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: R01-DK50238
GroupedDBID ---
-~X
.55
.GJ
.XZ
08P
29K
2WC
354
3O-
53G
5GY
5RE
5RS
8F7
AAWTL
AAYOK
AAYXX
ABOCM
ABPMR
ACGFO
ACIHN
ACNCT
ACPRK
ADBBV
AEAQA
AENEX
AFCHL
AFFNX
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ASPBG
AVWKF
AZFZN
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FRP
GROUPED_DOAJ
GX1
HYE
H~9
IAO
IEA
IHR
INH
IOF
IPO
J5H
KQ8
L7B
M1P
M5~
MVM
N4W
OBH
OCB
ODZKP
OFXIZ
OGEVE
OHH
OK1
OVD
OVIDX
OVT
P2P
P6G
RPM
TEORI
TR2
TVE
UHU
VH1
VVN
W2D
WH7
WOQ
WOW
X7M
XSB
YFH
YHG
YKV
YOC
ZGI
ZXP
ZY1
~H1
08G
36B
3V.
7RV
7X7
88A
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAKAS
ABUWG
ADZCM
AFKRA
BBNVY
BCR
BCU
BEC
BENPR
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
EBD
ECM
EIF
EMOBN
EX3
FEDTE
FYUFA
HCIFZ
HMCUK
HVGLF
IHW
INR
IOV
ISR
ITC
LK8
M0L
M7P
NAPCQ
NPM
OHT
PKN
PQQKQ
PROAC
PSQYO
Q2X
S0X
SJFOW
SV3
UKHRP
7X8
5PM
ID FETCH-LOGICAL-c430t-595de3cef8bd85b2a63fd4fa520156c8cdf1ffa6083af82bc12d06e0cf2b07a33
ISSN 0021-9738
IngestDate Thu Aug 21 13:44:46 EDT 2025
Fri Jul 11 04:44:41 EDT 2025
Wed Feb 19 01:35:25 EST 2025
Thu Apr 24 22:56:17 EDT 2025
Tue Jul 01 03:48:37 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c430t-595de3cef8bd85b2a63fd4fa520156c8cdf1ffa6083af82bc12d06e0cf2b07a33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Address correspondence to: Shlomo Melmed, Room 2015, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA. Phone: (310) 423-4691; Fax: (310) 423-0119; E-mail: Melmed@CSMC.edu.
OpenAccessLink http://www.jci.org/articles/view/7924/files/pdf
PMID 10545526
PQID 69235803
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_409825
proquest_miscellaneous_69235803
pubmed_primary_10545526
crossref_primary_10_1172_JCI7924
crossref_citationtrail_10_1172_JCI7924
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1999-11-01
PublicationDateYYYYMMDD 1999-11-01
PublicationDate_xml – month: 11
  year: 1999
  text: 1999-11-01
  day: 01
PublicationDecade 1990
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of clinical investigation
PublicationTitleAlternate J Clin Invest
PublicationYear 1999
Publisher American Society for Clinical Investigation
Publisher_xml – name: American Society for Clinical Investigation
References David (B24) 1995; 15
Adams (B16) 1998; 273
Wang (B4) 1996; 137
Bousquet (B5) 1997; 272
Hibi (B1) 1996; 74
Ray (B21) 1996; 97
Klingmuller (B14) 1995; 80
Auernhammer (B19) 1999; 96
Boutillier (B22) 1998; 1
Jiao (B13) 1996; 16
Hackett (B12) 1997; 272
Yetter (B25) 1995; 270
Damen (B26) 1995; 14
Hilton (B15) 1998; 95
You (B10) 1997; 272
Yoshimura (B31) 1995; 14
Ram (B11) 1997; 272
Narazaki (B32) 1998; 95
Kim (B36) 1996; 273
Ihle (B6) 1995; 60
Pei (B28) 1994; 33
Endo (B30) 1997; 387
Bousquet (B20) 1998; 273
Nicholson (B33) 1999; 18
D’Ambrosio (B27) 1995; 268
Kamura (B34) 1998; 12
Akita (B3) 1995; 95
Chesnokova (B2) 1998; 139
Horvath (B7) 1997; 9
Fauman (B9) 1996; 21
Bjorbaek (B17) 1998; 1
Bousquet (B8) 1999; 274
Auernhammer (B18) 1998; 12
Cohney (B35) 1999; 19
Feng (B23) 1994; 10
Yi (B29) 1995; 85
9658400 - Mol Endocrinol. 1998 Jul;12(7):954-61
7629131 - J Biol Chem. 1995 Aug 4;270(31):18179-82
9869640 - Genes Dev. 1998 Dec 15;12(24):3872-81
10196143 - J Biol Chem. 1999 Apr 16;274(16):10723-30
9430658 - J Biol Chem. 1998 Jan 16;273(3):1285-7
9287352 - J Biol Chem. 1997 Sep 12;272(37):23376-81
9889194 - EMBO J. 1999 Jan 15;18(2):375-85
7528537 - Biochemistry. 1994 Dec 27;33(51):15483-93
8521813 - EMBO J. 1995 Nov 15;14(22):5557-68
8191586 - Trends Genet. 1994 Feb;10(2):54-8
7883977 - J Clin Invest. 1995 Mar;95(3):1288-98
9099700 - J Biol Chem. 1997 Apr 18;272(16):10551-7
7796808 - EMBO J. 1995 Jun 15;14(12):2816-26
11081181 - Pituitary. 1998 Apr;1(1):33-43
8621768 - J Clin Invest. 1996 Apr 15;97(8):1852-9
9111009 - J Biol Chem. 1997 Apr 25;272(17):11128-32
9564824 - Endocrinology. 1998 May;139(5):2209-16
10373548 - Mol Cell Biol. 1999 Jul;19(7):4980-8
9507021 - J Biol Chem. 1998 Mar 20;273(12):7099-106
7528577 - Blood. 1995 Jan 1;85(1):87-95
7889566 - Cell. 1995 Mar 10;80(5):729-38
8943354 - Mol Cell Biol. 1996 Dec;16(12):6985-92
9789053 - Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13130-4
8770918 - Endocrinology. 1996 Jul;137(7):2947-53
8524272 - Mol Cell Biol. 1995 Dec;15(12):7050-8
8987394 - Trends Biochem Sci. 1996 Nov;21(11):413-7
7716523 - Science. 1995 Apr 14;268(5208):293-7
10359822 - Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6964-9
9419338 - Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):114-9
9211920 - J Biol Chem. 1997 Jul 11;272(28):17694-702
8834766 - J Mol Med (Berl). 1996 Jan;74(1):1-12
9202126 - Nature. 1997 Jun 26;387(6636):921-4
9660946 - Mol Cell. 1998 Mar;1(4):619-25
8607368 - Adv Immunol. 1995;60:1-35
9069254 - Curr Opin Cell Biol. 1997 Apr;9(2):233-9
8781235 - Science. 1996 Sep 20;273(5282):1717-9
References_xml – volume: 273
  start-page: 7099
  year: 1998
  ident: B20
  publication-title: J Biol Chem
  doi: 10.1074/jbc.273.12.7099
– volume: 268
  start-page: 293
  year: 1995
  ident: B27
  publication-title: Science
  doi: 10.1126/science.7716523
– volume: 272
  start-page: 10551
  year: 1997
  ident: B5
  publication-title: J Biol Chem
  doi: 10.1074/jbc.272.16.10551
– volume: 95
  start-page: 1288
  year: 1995
  ident: B3
  publication-title: J Clin Invest
  doi: 10.1172/JCI117779
– volume: 1
  start-page: 33
  year: 1998
  ident: B22
  publication-title: Pituitary
  doi: 10.1023/A:1009966808106
– volume: 387
  start-page: 921
  year: 1997
  ident: B30
  publication-title: Nature
  doi: 10.1038/43213
– volume: 96
  start-page: 6964
  year: 1999
  ident: B19
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.96.12.6964
– volume: 33
  start-page: 15483
  year: 1994
  ident: B28
  publication-title: Biochemistry
  doi: 10.1021/bi00255a030
– volume: 16
  start-page: 6985
  year: 1996
  ident: B13
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.16.12.6985
– volume: 10
  start-page: 54
  year: 1994
  ident: B23
  publication-title: Trends Genet
  doi: 10.1016/0168-9525(94)90149-X
– volume: 15
  start-page: 7050
  year: 1995
  ident: B24
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.15.12.7050
– volume: 85
  start-page: 87
  year: 1995
  ident: B29
  publication-title: Blood
  doi: 10.1182/blood.V85.1.87.bloodjournal85187
– volume: 74
  start-page: 1
  year: 1996
  ident: B1
  publication-title: J Mol Med
  doi: 10.1007/BF00202068
– volume: 273
  start-page: 1285
  year: 1998
  ident: B16
  publication-title: J Biol Chem
  doi: 10.1074/jbc.273.3.1285
– volume: 60
  start-page: 1
  year: 1995
  ident: B6
  publication-title: Adv Immunol
  doi: 10.1016/S0065-2776(08)60582-9
– volume: 272
  start-page: 17694
  year: 1997
  ident: B11
  publication-title: J Biol Chem
  doi: 10.1074/jbc.272.28.17694
– volume: 1
  start-page: 619
  year: 1998
  ident: B17
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(00)80062-3
– volume: 139
  start-page: 2209
  year: 1998
  ident: B2
  publication-title: Endocrinology
  doi: 10.1210/endo.139.5.6016
– volume: 21
  start-page: 413
  year: 1996
  ident: B9
  publication-title: Trends Biochem Sci
  doi: 10.1016/S0968-0004(96)10059-1
– volume: 272
  start-page: 11128
  year: 1997
  ident: B12
  publication-title: J Biol Chem
  doi: 10.1074/jbc.272.17.11128
– volume: 9
  start-page: 233
  year: 1997
  ident: B7
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/S0955-0674(97)80067-1
– volume: 95
  start-page: 13130
  year: 1998
  ident: B32
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.95.22.13130
– volume: 19
  start-page: 4980
  year: 1999
  ident: B35
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.19.7.4980
– volume: 12
  start-page: 3872
  year: 1998
  ident: B34
  publication-title: Genes Dev
  doi: 10.1101/gad.12.24.3872
– volume: 12
  start-page: 954
  year: 1998
  ident: B18
  publication-title: Mol Endocrinol
  doi: 10.1210/mend.12.7.0140
– volume: 14
  start-page: 5557
  year: 1995
  ident: B26
  publication-title: EMBO J
  doi: 10.1002/j.1460-2075.1995.tb00243.x
– volume: 97
  start-page: 1852
  year: 1996
  ident: B21
  publication-title: J Clin Invest
  doi: 10.1172/JCI118615
– volume: 270
  start-page: 18179
  year: 1995
  ident: B25
  publication-title: J Biol Chem
  doi: 10.1074/jbc.270.31.18179
– volume: 18
  start-page: 375
  year: 1999
  ident: B33
  publication-title: EMBO J
  doi: 10.1093/emboj/18.2.375
– volume: 95
  start-page: 114
  year: 1998
  ident: B15
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.95.1.114
– volume: 14
  start-page: 2816
  year: 1995
  ident: B31
  publication-title: EMBO J
  doi: 10.1002/j.1460-2075.1995.tb07281.x
– volume: 273
  start-page: 1717
  year: 1996
  ident: B36
  publication-title: Science
  doi: 10.1126/science.273.5282.1717
– volume: 272
  start-page: 23376
  year: 1997
  ident: B10
  publication-title: J Biol Chem
  doi: 10.1074/jbc.272.37.23376
– volume: 137
  start-page: 2947
  year: 1996
  ident: B4
  publication-title: Endocrinology
  doi: 10.1210/endo.137.7.8770918
– volume: 274
  start-page: 10723
  year: 1999
  ident: B8
  publication-title: J Biol Chem
  doi: 10.1074/jbc.274.16.10723
– volume: 80
  start-page: 729
  year: 1995
  ident: B14
  publication-title: Cell
  doi: 10.1016/0092-8674(95)90351-8
– reference: 7528577 - Blood. 1995 Jan 1;85(1):87-95
– reference: 9869640 - Genes Dev. 1998 Dec 15;12(24):3872-81
– reference: 7883977 - J Clin Invest. 1995 Mar;95(3):1288-98
– reference: 8191586 - Trends Genet. 1994 Feb;10(2):54-8
– reference: 8524272 - Mol Cell Biol. 1995 Dec;15(12):7050-8
– reference: 8987394 - Trends Biochem Sci. 1996 Nov;21(11):413-7
– reference: 9660946 - Mol Cell. 1998 Mar;1(4):619-25
– reference: 8781235 - Science. 1996 Sep 20;273(5282):1717-9
– reference: 10196143 - J Biol Chem. 1999 Apr 16;274(16):10723-30
– reference: 7629131 - J Biol Chem. 1995 Aug 4;270(31):18179-82
– reference: 8521813 - EMBO J. 1995 Nov 15;14(22):5557-68
– reference: 9658400 - Mol Endocrinol. 1998 Jul;12(7):954-61
– reference: 9564824 - Endocrinology. 1998 May;139(5):2209-16
– reference: 8621768 - J Clin Invest. 1996 Apr 15;97(8):1852-9
– reference: 8834766 - J Mol Med (Berl). 1996 Jan;74(1):1-12
– reference: 9287352 - J Biol Chem. 1997 Sep 12;272(37):23376-81
– reference: 9419338 - Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):114-9
– reference: 9789053 - Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13130-4
– reference: 7716523 - Science. 1995 Apr 14;268(5208):293-7
– reference: 8607368 - Adv Immunol. 1995;60:1-35
– reference: 7796808 - EMBO J. 1995 Jun 15;14(12):2816-26
– reference: 7889566 - Cell. 1995 Mar 10;80(5):729-38
– reference: 9099700 - J Biol Chem. 1997 Apr 18;272(16):10551-7
– reference: 9211920 - J Biol Chem. 1997 Jul 11;272(28):17694-702
– reference: 10373548 - Mol Cell Biol. 1999 Jul;19(7):4980-8
– reference: 9202126 - Nature. 1997 Jun 26;387(6636):921-4
– reference: 8770918 - Endocrinology. 1996 Jul;137(7):2947-53
– reference: 7528537 - Biochemistry. 1994 Dec 27;33(51):15483-93
– reference: 9111009 - J Biol Chem. 1997 Apr 25;272(17):11128-32
– reference: 9430658 - J Biol Chem. 1998 Jan 16;273(3):1285-7
– reference: 8943354 - Mol Cell Biol. 1996 Dec;16(12):6985-92
– reference: 9069254 - Curr Opin Cell Biol. 1997 Apr;9(2):233-9
– reference: 11081181 - Pituitary. 1998 Apr;1(1):33-43
– reference: 10359822 - Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6964-9
– reference: 9507021 - J Biol Chem. 1998 Mar 20;273(12):7099-106
– reference: 9889194 - EMBO J. 1999 Jan 15;18(2):375-85
SSID ssj0014454
Score 1.9324389
Snippet Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1277
SubjectTerms Animals
Catalysis
Cell Line
DNA-Binding Proteins - metabolism
Down-Regulation
Growth Inhibitors - pharmacology
Interleukin-6
Intracellular Signaling Peptides and Proteins
Janus Kinase 2
Leukemia Inhibitory Factor
Lymphokines - pharmacology
Mice
Models, Biological
Phosphorylation
Pituitary Gland - metabolism
Pro-Opiomelanocortin - metabolism
Protein Tyrosine Phosphatase, Non-Receptor Type 11
Protein Tyrosine Phosphatase, Non-Receptor Type 6
Protein Tyrosine Phosphatases - metabolism
Protein Tyrosine Phosphatases - physiology
Protein-Tyrosine Kinases - metabolism
Proteins - physiology
Proto-Oncogene Proteins
Repressor Proteins
SH2 Domain-Containing Protein Tyrosine Phosphatases
Signal Transduction
STAT3 Transcription Factor
Suppressor of Cytokine Signaling 3 Protein
Suppressor of Cytokine Signaling Proteins
Time Factors
Trans-Activators - metabolism
Transcription Factors
Transfection
Title Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor
URI https://www.ncbi.nlm.nih.gov/pubmed/10545526
https://www.proquest.com/docview/69235803
https://pubmed.ncbi.nlm.nih.gov/PMC409825
Volume 104
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLbKICEuiJ2y-oC4oEA2O8kRKlA7aACpM9LcqnhTI9JkBIkQXPjrPNupnbYjsVyi1nUW5X19fs_-3meEnksVEVYwFYSCqiBVMQuYEklAYagUOc8ZNfOQJx_p_Cw9Pifnk8mvEWup79gr_vPSupL_sSq0gV11lew_WNZdFBrgM9gXjmBhOP6VjRfNumKVWSbXLEEjrfByOf8cRJaR-Wm2DBJorOv2u6k6r7q-6jRPDvxme6Er7-uyaSEB7SrNeBRWSlaHpLXsv8hNVUKru4fdm2cczvrCMhPSujLLyqt3-GX-t23_DUYhyzPRvD-_or_U9PvKix0AZj0nV9YbOyO7XNftpvXzFEbbIHLzFNu6gSgoMqvl4nyv3Xt4AFkx8qRRPGzvIoevdmefQ4-faQXZ49kiK2wx9q6m9t5Y5xiIJvfJ4tVw4hV0Fe5nc_LFB7cMlaZkkPG2j26rrvWJr4cTd8OZgxxln2o7il1Ob6Ibg4XwG4ugW2gim9vo2slAq7iDeg8kbICEAUjYAAkDkLAFEnZAwg5I-BIgYQckzH7gLZCwBxK2QLqLzt6_O53Ng2E_joCnSdgFpCBCJlyqnImcsLikiRKpKkms6_F5zoWKlCopRPWlymPGo1iEVIYcPECYlUlyDx01bSMfIMwU2JOnnKQlhJRcQtYf5krwvBCJAg8xRS-2r3XFB7F6vWdKvdoz3BRh1_HC6rMcdnm2tcsKfKdeEAMQA-RXtNCF4mEyRfetlUaXgMyCxHSK6I79XAetyr77S1OtjTp7GhZ5TB7--bkeoev-f_IYHXVfe_kEItyOPTUo_A14ELEg
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibitory+roles+for+SHP-1+and+SOCS-3+following+pituitary+proopiomelanocortin+induction+by+leukemia+inhibitory+factor&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Bousquet%2C+Corinne&rft.au=Susini%2C+Christiane&rft.au=Melmed%2C+Shlomo&rft.date=1999-11-01&rft.issn=0021-9738&rft.volume=104&rft.issue=9&rft.spage=1277&rft.epage=1285&rft_id=info:doi/10.1172%2FJCI7924&rft.externalDBID=n%2Fa&rft.externalDocID=10_1172_JCI7924
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon